-
British Journal of Pharmacology Oct 19781 The effects of 5 mg/kg acebutolol given intravenously were investigated in anaesthetized dogs after (a) ligation of the left anterior descending coronary artery and...
1 The effects of 5 mg/kg acebutolol given intravenously were investigated in anaesthetized dogs after (a) ligation of the left anterior descending coronary artery and (b) coronary reperfusion following 60 min of ligation of the anterior descending coronary artery. 2 Coronary artery ligation produced, after 4 to 6 h, persistent multiple ventricular ectopic beats and abnormalities of R and T waves and of the S-T segment. Administration of acebutolol, after the development of persistent ventricular arrhythmias, restored normal sinus rhythm within 5 min of injection. Electrocardiographic abnormalities were also reduced. 3 Coronary artery reperfusion (following 60 min of ligation) resulted in multiple ventricular ectopic beats, ventricular tachycardia and/or ventricular fibrillation. Pretreatment with acebutolol, 15 min before starting reperfusion, markedly reduced the arrhythmias. 4 Acebutolol did not affect peak inspiratory airway pressure. 5 Acebutolol produced significant bradycardia and slight, transient, hypotension. It was without effect on left ventricular systolic pressure, left ventricular end-diastolic pressure, cardiac output or pulmonary arterial pressure. 6 These results suggest beneficial effects of acebutolol in myocardial ischaemia and coronary reperfusion, without any significant risk of cardiodepression or bronchospasm.
Topics: Acebutolol; Anesthesia; Animals; Arrhythmias, Cardiac; Coronary Disease; Dogs; Electrocardiography; Female; Hemodynamics; Male; Perfusion
PubMed: 708995
DOI: 10.1111/j.1476-5381.1978.tb17299.x -
Lancet (London, England) Jul 1975In a double-blind randomised study, single intravenous doses of propranolol (0-1 mg. per kg.), practolol (1 mg. per kg.), acebutolol (1 mg. per kg.), or placebo were... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
In a double-blind randomised study, single intravenous doses of propranolol (0-1 mg. per kg.), practolol (1 mg. per kg.), acebutolol (1 mg. per kg.), or placebo were each administered at weekly intervals to six healthy volunteers. Forced expiratory volume in 1 second (F.E.V.1), resting and exercise heart-rate, and resting and exercise peak flow-rate (P.F.R.) were determined before and at 2, 3, 4, and 6 hours after each treatment. Venous blood-samples were also obtained at these times. Compared with placebo, resting heart-rate was reduced after all three drugs, but the corresponding differences in exercise heart-rate were much greater, more consistent, and of greater statistical significance. At 2, 3, and 4 hours when acebutolol and propranolol produced equivalent cardiac beta-blocking activity (judged by reductions in exercise heart-rate), their mean plasma concentratios were in the ratio of about 8/1; and at 2 hours when practolol and acebutolol gave rise to almost equivalent cardiac beta blockade, their mean plasma concentratio ration was 3/1. At times, reductions in F.E.V.1 and resting P.F.R. after propranolol (but not after practolol or acebutolol) were significantly greater than the corresponding changes after placebo. The reductions in exercies P.F.R. after propranolol (6 hours) and acebutolol (4 hours) (but not after practolol) were significantly greater than the changes after placebo. Changes in F.E.V.1, resting and exercise P.F.R. after propranolol, and the corresponding changes after practolol, were significantly different, all of which confirmed that practolol was more cardioselective than propranolo. In general, the reductions in F.E.V.1 and resting P.F.R. after acebutolol were slightly smaller than after propranolol, excepting at 6 hours when the difference between them was significant. The reductions in exercise P;F.R. after acebutolol and propranolol were of the same order, there being no significant differences between the two, whereas the reductions after acebutolol were clearly greater than the corresponding changes after practolol, the differences being significant at 2, 3, and 4 hours.
Topics: Acebutolol; Adult; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Exercise Test; Female; Forced Expiratory Flow Rates; Heart; Heart Rate; Humans; Injections, Intravenous; Lung; Male; Physical Exertion; Placebos; Practolol; Propranolol; Rest
PubMed: 49736
DOI: 10.1016/s0140-6736(75)90001-x -
Soins. Cardiologie Mar 1985
Topics: Acebutolol; Angina Pectoris; Arrhythmias, Cardiac; Humans; Hypertension
PubMed: 3847165
DOI: No ID Found -
Clinical Pharmacology and Therapeutics Apr 1980To assess the effects of acebutolol and propranolol on resting left ventricular function, 21 patients with coronary artery disease were studied. A baseline... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
To assess the effects of acebutolol and propranolol on resting left ventricular function, 21 patients with coronary artery disease were studied. A baseline echocardiogram was obtained on day 1, and in a double-blind, randomized, crossover study the patients received 40 mg propranolo every 8 hr for 1 wk, 300 mg acebutolol every 8 hr for 1 wk, and 1 capsule placebo every 8 hr for 1 wk. On days 8, 15, and 22, after an echocardiogram at 7:30 A.M. (i.e., 7.5 hr after the midnight dose), they received double-blind randomized, crossover medications (acebutolol 300 mg, propranolol 40 mg, or placebo). The echocardiogram was repeated at 1.2, and 4 hr after placebo or propranolol and at 2, 3, and 5 hr after acebutolol. The left ventricular end diastolic dimension, left ventricular end systolic dimension, percent systolic shortening of the left ventricular minor axis, and ejection fraction were determined. We found that there was no significant difference between control values for any of the above parameters and those obtained at 1, 2, 4, or 7.5 hr after propranolol or placebo and at 2, 3, 5, or 7.5 hr after acebutolol. We conclude that in the doses used, acebutolol and propranolol do not induce depression of resting left ventricular function in patients with coronary artery disease who have normal or near normal left ventricular function at rest.
Topics: Acebutolol; Adult; Double-Blind Method; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Contraction; Placebos; Propranolol
PubMed: 7357803
DOI: 10.1038/clpt.1980.64 -
Cardiology 1978
Topics: Acebutolol; Adult; Angina Pectoris; Blood Pressure; Cardiac Output; Electrocardiography; Humans; Middle Aged
PubMed: 688290
DOI: 10.1159/000169940 -
European Journal of Clinical... 1986The beta-adrenergic selectivity of diacetolol, the major metabolite of acebutolol, has been compared with that of acebutolol, metoprolol and propranolol in 11 normal... (Clinical Trial)
Clinical Trial Comparative Study
The beta-adrenergic selectivity of diacetolol, the major metabolite of acebutolol, has been compared with that of acebutolol, metoprolol and propranolol in 11 normal subjects. Bronchial and cardiac beta-adrenoceptor blockade were assessed on separate occasions after diacetolol 600 mg, acebutolol 400 mg, metoprolol 200 mg, propranolol 80 mg and placebo. Bronchial beta-adrenoceptor blockade was assessed as the displacement of the bronchodilator dose response curve to inhaled isoprenaline after each beta blocking drug compared to placebo and expressed as the dose ratio. Bronchodilatation was measured as change in specific airway conductance (sGaw) in the body plethysmograph. Cardiac beta-adrenoceptor blockade was assessed as the percentage reduction in exercise heart rate during the 5th minute of exercise at 70% of the subject's maximum work rate. There was a significant reduction in exercise heart rate with all 4 beta-blocking drugs when compared with placebo, 22% for diacetolol, 24% for acebutolol, 25% for propranolol and 28% for metoprolol. The reduction with metoprolol was significantly greater than the reduction with the other three beta-adrenoceptor antagonists. Mean dose ratios for the airway isoprenaline dose response curves after each of the 4 beta-blocking drugs were 2.4 for diacetolol, 2.7 for metoprolol, 8 for acebutolol and 72 for propranolol. The difference between diacetolol and metoprolol was not significant. Thus diacetolol appears to be more cardioselective than acebutolol and both are more cardioselective than propranolol in man. Metoprolol is probably more cardioselective than diacetolol though interpretation of the differences in exercise heart rate is complicated by the fact that diacetolol has some intrinsic sympathomimetic activity.
Topics: Acebutolol; Adrenergic beta-Antagonists; Airway Resistance; Dose-Response Relationship, Drug; Heart Rate; Humans; Isoproterenol; Metoprolol; Physical Exertion; Propranolol; Receptors, Adrenergic, beta
PubMed: 2872056
DOI: 10.1007/BF00615958 -
Arzneimittel-Forschung 1984The antihypertensive efficacy and the acceptability of nifedipine (NI, Adalat) and the usefulness of its combination with a beta 1-selective blocking drug, acebutolol... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
The antihypertensive efficacy and the acceptability of nifedipine (NI, Adalat) and the usefulness of its combination with a beta 1-selective blocking drug, acebutolol (AC), were studied in a placebo controlled trial on 15 patients with moderate hypertension. The study consisted of three phases: 1. An acute test, including the single blind comparison of three different single doses of NI (5, 10, 20 mg), alone and in combination with AC 200 mg, with placebo and with AC alone (200 mg), showed an early hypotensive effect, with no differences for the three doses of NI, reaching the maximum between 50 and 240 min, greater than the one of AC, and smaller in comparison with the one of the combinations, which didn't differ at the three doses of NI. Heart rate (HR) and side effects, instead, increased with the increasing doses of NI, suggesting a worse acceptability for the greater doses. 2. A long-term treatment, including a double-blind comparison of three separate periods of 4 weeks of treatment with NI (10 mg three times a day), AC (200 mg three times a day) and with the combination of the same doses, showed a significant reduction of systolic and diastolic blood pressure (BP) for each treatment, not significantly different at rest for the three single drugs but greater for the combined treatment, assuring also a better control of systolic BP during exercise. A reduced number of side effects was seen with the combined therapy which seems to contribute to a better compliance.(ABSTRACT TRUNCATED AT 250 WORDS)
Topics: Acebutolol; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Myocardial Contraction; Nifedipine; Random Allocation
PubMed: 6386007
DOI: No ID Found -
Circulation Jun 1982
Clinical Trial Randomized Controlled Trial
Topics: Acebutolol; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Hemodynamics; Humans; Male; Middle Aged; Nitroglycerin; Physical Exertion; Propranolol; Random Allocation
PubMed: 6804109
DOI: 10.1161/01.cir.65.6.1119 -
European Journal of Clinical... May 1980
Comparative Study
Topics: Acebutolol; Adult; Erythrocytes; Female; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Renal Dialysis
PubMed: 7418713
DOI: 10.1007/BF00558446 -
European Journal of Clinical... 1975Six unselected males suffering from documented coronary insufficiency and grade II to III angina were submitted to graded multistage treadmill exercise test on 3... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
Six unselected males suffering from documented coronary insufficiency and grade II to III angina were submitted to graded multistage treadmill exercise test on 3 separate occasions, 3.5 hours after ingestion of either 0, 200 or 400 mg of acebutolol, a new cardioselective beta-blocker. Control measures included the random allocation to 6 balanced sequences of administration, the rigid standardisation of double-blind experimental conditions and measurements, and two types of variance analysis (latin-square and split-plot). Performance was evaluated by measuring time elapsed before occurrence of anginal pain and ECG changes, peak heart rate, peak double product (heart rate x systolic pressure), and peak oxygen consumption. The mean values for all 5 criteria showed improvement with the 200 mg dose of acebutolol, and even more so with 400 mg, but this overall effect resulted mainly from the excellent response of 3 of the patients. When patients were grouped into 2 categories of responders and non-responders, a significant Dose x Category interaction was found for all criteria. Furthermore, maximal response under acebutolol was negatively correlated with values under placebo (0 mg); this correlation reached significance for peak heart rate and peak double product. It is concluded that (a) in responders, the beneficial effect of acebutolol was significant on all 5 criteria (p less than 0.05), (b) patients definitely fell into 2 categories of responsiveness and (c) the sensitivity of responders was partly linked to their performance under placebo and partly to unidentified individual factors.
Topics: Acebutolol; Adult; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Exercise Test; Heart Rate; Humans; Male; Middle Aged; Oxygen Consumption
PubMed: 786672
DOI: 10.1007/BF00616410